



# 2023 US Sustainability Highlights Report



Teva, a leading global pharmaceutical company, delivers quality medicines to help improve the health of millions of patients every day. Healthy Future, our renewed sustainability strategy, is focused on healthy people, a healthy planet and a healthy business, with targets including achieving net zero emissions across our operations and value chain by 2045.

## Here are highlights of our 2023 sustainability efforts in the US.

Unless mentioned otherwise, the information included in this US Sustainability Highlights Report refers to our activities and operations in the US.






### Our Footprint

Our vast presence, significant manufacturing capacity and diversified supply chain help us reach patients.







### Our Medicines

We develop and supply generic, biosimilar and innovative medicines, as well as finished doses and active pharmaceutical ingredients.






**Globally:**  
**2,100+**  
products in our portfolio and pipeline, including **1,834** generic medicines

**Leading supplier** of quality medicines on the World Health Organization's Essential Medicines List, manufacturing **56%** of medicines<sup>5</sup> on this list of treatments for priority health needs



### Our Economic Impact

Our generic medicines generate savings for healthcare systems and help patients access treatments at lower costs, without compromising quality. Teva also creates societal value as an employer and a manufacturer. Our spending and income, both directly and indirectly through our supply chain, initiate a production cycle that supports more jobs and further contributes to the economy and communities.<sup>6</sup>



## Access to Medicines and Healthcare

Increasing access to medicines is fundamental to improving the health of patients. Our generic medicines offer more affordable options, and our innovative medicines address unmet health needs.



## Partnering to increase access to care

In partnership with [Direct Relief](#) and the [National Association of Free & Charitable Clinics \(NAFC\)](#), we launched [Community Routes: Access to Mental Health Care](#), an innovative program to advance access to care for uninsured and underserved patients suffering from depression and anxiety.<sup>10</sup> Through this program, Teva donates commonly used generic medicines and provides grant funding to eligible free and charitable clinics.

### Launched in:

3 states in 2022 and 7 more in 2023

\$2M

in grant funding provided over 2 years

17.7M

doses of medicine donated in 2023, worth \$11.3M<sup>11</sup>

With grant funding from Teva, clinics implemented or expanded activities, including depression, anxiety and adverse childhood experience screenings and culturally and linguistically relevant behavioral health services and resources.

28,000

people reached from November 2022 to October 2023 through clinic programs, including:

~7,000

directly (e.g., through provider visits and screenings)

21,000+

indirectly (e.g., through outreach, staff and volunteer training and community events)

## Advocating for patients

We supported patient advocacy groups in educating communities about tardive dyskinesia and Huntington's disease, reaching:<sup>12</sup>

700,000

people, including patients, caregivers and community members

19

nongovernmental organizations (NGOs)

## Pricing medicines

Generic and innovative medicines are both part of a cycle of innovation, affordability and accessibility. Teva regularly reviews prices in the context of market conditions, availability and production costs. Relative to 2022, across our innovative medicine portfolio:


3.53%

average list price increase

0.16%

average net price decrease

### Community Routes: Access to Mental Health Care US Footprint



## Providing medicines to those in need



### Medicine donations

43M+

single doses of medicine, worth \$47M,<sup>11</sup> donated to US safety net clinics through NGO partners



### Patient assistance programs

1.6M+

single doses of medicine, worth \$199M,<sup>11</sup> provided through patient assistance programs, including the Teva Cares Foundation, to provide certain medicines at no cost to patients who meet insurance and income criteria



### Emergency and disaster relief

Medicines donated through Direct Relief to support those impacted by earthquakes in Turkey, Haiti and Morocco, wildfires in Maui, Hurricane Idalia and the conflict in Ukraine



# Inclusion and Diversity

We weave inclusion and diversity (I&D) into every aspect of our business—including our workforce, supply chain and communications. This drives innovation and enables us to better meet the needs of patients, while also contributing to the success of our business.



## Maintaining a diverse workforce

We seek to recruit candidates of different backgrounds. Diversity of thought and skill drives our collective creativity and success, creating high-performing teams that understand the diverse needs of patients best.



## Fostering an inclusive culture


Our employee resource groups (ERGs) foster allyship, offering networking opportunities, mentoring and leadership training, while providing a platform to take action, express unique voices and create communities. They include:

- Abilities (for those working with disabilities)
- Asian
- Black Heritage
- Latinx
- MERGE (multigenerational)
- Pride
- Women
- Working Families
- Vets

## Working with diverse suppliers

We aim to engage key external stakeholders, build partnerships and leverage our advocacy group memberships to help advance diversity in our supply chain. These efforts led to a 68% increase in the number of small and diverse suppliers in our network (vs. 2022),<sup>14</sup> fostering inclusivity and economic growth in the communities we serve.

### Suppliers Across Diverse Business Types<sup>15</sup>



We also worked with 196 minority-owned businesses—a 26% increase from 2022.<sup>17</sup>

## Earning recognition

Our efforts to foster an inclusive and diverse workplace have been recognized. We also increased employee membership in the Healthcare Businesswomen's Association, the premier group promoting women's leadership in healthcare.





# Environmental Sustainability

We reduce our impact on the environment to improve the health of the planet, which is inherently linked to the health of those who inhabit it, including patients.



## Minimizing our footprint

Our actions are focused on Climate Action and Resilience and Pharmaceuticals in the Environment. We also proactively manage Waste and Circularity and Product Stewardship. Since 2022, in the US, we reduced:



## Implementing innovative projects

We executed the Electronic Patient Package Insert project with the US Food and Drug Administration to replace paper copies of the patient package insert for products distributed in the US.

Implemented for almost **90%** of our products, saving **24,000** trees annually

Reduced CO<sub>2</sub> by **844.2** metric tons annually,<sup>18</sup> saving **\$1.1M** per year

## Making changes at our Florida sites

- Reduced total energy consumption by 326,100 kWh (4.5% decrease from 2022)
- Upgraded hot water boiler, resulting in annual energy savings of \$21,000 and reducing the site's carbon footprint by 164 metric tons
- Installed new remote-operated controllers to monitor heating, ventilation and air conditioning units as part of Energy Star program

We continued our Energy Treasure Hunt program, in line with the US Environmental Protection Agency's Energy Star program. Cross-functional teams searched facilities for methods to save energy, and sites enhanced operational capabilities.

### Globally:

Our near-term GHG emissions reduction targets have been **approved by the Science Based Targets initiative (SBTi)**, providing external validation that they are grounded in science and in line with global goals to combat climate change.

We take a holistic approach to addressing antimicrobial resistance (AMR). We were one of six companies to participate in a **AMR Industry Alliance (AMRIA) certification program pilot**, and one of the first two companies to receive the British Standards Institution (BSI) Manufacturing Certificate for Responsible Manufacturing for two variations of an antibiotic product.

We also hold our suppliers to high environmental standards. **We assessed 60.2% of significant suppliers on sustainability topics**,<sup>19</sup> and 32.5% of significant suppliers scored above 60 points (of 100) by EcoVadis.

## Advancing industry actions

We partner to promote environmental education and dialogue, as well as to advance industry actions. Teva is a member of the Pharmaceutical Supply Chain Initiative (PSCI), AMRIA, Biopharma Sustainability Roundtable (BSRT), Pharmaceutical Environment Group (PEG) and more.

1. Head count is as of December 31, 2023. 2. Sites include commercial, R&D, manufacturing, distribution and Abbreviated New Drug Application (ANDA) sites throughout 2023, including Puerto Rico. 3. Teva had operations in the states of Florida, Massachusetts, Mississippi, New Jersey, New York, Ohio, Pennsylvania, Utah and Virginia throughout 2023. 4. Data reflects products available in product catalog. 5. Number is based on INN 2023 IQVIA data. 6. This analysis includes the economic impact of all Teva activities. Indirect data reflects domestic and foreign supply chain effects around the world. Data presented for GDP, labor income and generic savings includes number rounding for ease of reporting. For an explanation of our Economic Impact and Generic Medicine Savings methodology, visit WifOR's [methodological summary](#). 7. In 2023, WifOR updated its global methodology for assessing GDP. Teva's GDP contribution (direct and indirect) for the business years 2021 and 2022 have been revised to enhance accuracy, addressing discrepancies identified within the input data, thus ensuring its reliability. 8. Labor income refers to the sum of wages and salaries generated from, and as a result of, Teva's activities. Data from Teva; calculation by WifOR. Multiplier Benchmarks from WifOR-Global Multiregional Input-Output Model (2023). 9. Jobs refers to those created by, and as a result of, Teva's activities. 10. This is one of eight access to medicines programs Teva committed to launch globally by 2025. 11. Value is based on wholesale acquisition cost (WAC). 12. Data reported by patient advocacy groups. 13. Teva has provided the means for employees to identify their gender preference, including undeclared and non-binary. 14. Status as a diverse supplier or small business supplier is validated at the time of spend, captured using applicable criteria. Data was extracted in December 2023 and excludes minority-owned businesses. 15. Data was extracted in December 2023 and is based on fiscal years 2022 and 2023. Not all groups are highlighted in the graph depicted. 16. HUBZone is a US Small Business Administration program for small companies that operate and employ people in Historically Underutilized Business Zones. 17. Data was extracted in May 2024. 18. This calculation includes the direct impact from eliminating the paper insert. The conversion factor used is generally recognized as the average for paper mills, including the fuel and chemicals used to harvest the trees and process the material. 19. Significant suppliers are identified based on a defined set of criteria, which include businesses with the highest spend, those responsible for over 60% of the scope 3 emissions, those connected to antimicrobial resistance (AMR) and those targeted for sustainability initiatives based on a sustainability maturity model.

This 2023 US Sustainability Highlights Report contains forward-looking statements, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties. For a discussion of these risks and uncertainties, please refer to our [2023 Healthy Future Report](#), including the section captioned "Cautionary Note Regarding Forward Looking Statements."